Marco Pappagallo, MD is a Clinical Professor of Anesthesiology, Albert Einstein College of Medicine, Bronx, NY. After completing a Neurology Residency and subsequently a 3-year clinical and research fellowship in pain medicine at the Johns Hopkins University, Baltimore, MD, Dr Pappagallo became Director of the Hopkins Chronic Pain Neurology Program. Later he was Director of the Comprehensive Pain Center at the Hospital for Joint Diseases (now NYU Langone Orthopedic Hospital), NYC, NY. In 2006 he was Professor of Anesthesiology and Director of Pain Research at the Mount Sinai Medical Center, NYC, NY. Since 2014 he has been Clinical Professor, Dept of Anesthesiology, Albert Einstein Coll of Medicine, Bronx, NY.
In 2010 Dr. Pappagallo co-founded Novapharma Therapeutics (NTP, Wayne, PA) where he served as Chief Medical Officer (CMO). From 2012 to 2017, he collaborated with Grünenthal-USA, Morristown, NJ in the field of rare diseases and pain. From 2018 to 2020 he was the CMO of CerSci Therapeutics, Dallas, TX. In 2021 Dr Pappagallo joined Relmada Therapeutics as a Scientific Advisor, and in 2022, as acting CMO, he led the completion of the early clinical development (including the Human Abuse Potential program) of a novel NMDAR antagonist in Major Depressive Disorder and helped conduct the translational clinical development of novel neuroplastogens and psychedelics.
Dr. Marco Pappagallo has been recognized as a leading academic expert in neurosciences and pain medicine. He was named Professor of "Chiara Fama" at the University of Rome 'La Sapienza," Italy. He was the recipient of a host of NIH and industry grants. He lectured extensively nationally and internationally. He edited and authored four textbooks and more than 150 peer-reviewed publications. Dr Pappagallo holds several patents for novel non-opioid analgesic treatments and therapeutic use of psychedelics. He was a co-founder of the Pain Impact in Rare Diseases Consortium Initiative. He has been a consultant and scientific advisory board member for a number of biopharma companies and consultant to the US Department of Defense. Over the years he also received multiple awards of excellence in patient care, eg, Most Compassionate Doctor Recognition Award, Patients' Choice Award, Best Doctors in America® award, Bikur Cholim Physician of the Year Award (Mazkereth Frima D'Munkakacs, NYC).